Christophe Beauduin

Cooley advised AllRock Bio, a clinical-stage biotechnology company focused on advancing therapies for cardiopulmonary and fibrotic diseases, on its $50 million Series A financing to advance AllRock’s lead molecule, ROC-101, a first-in-class, oral pan-rho-associated protein kinase inhibitor to treat pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease.

Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.

Cooley advised Cerberus Ventures, a venture fund established in 2023 to invest in early-stage companies in sectors important to government and innovators, as lead investor in Syntis Bio’s $38 million financing. Partners Matthew Bartus, Marc Recht and Christophe Beauduin led the Cooley team advising Cerberus Ventures.

Cooley advised BioMarin Pharmaceutical (Nasdaq: BMRN), a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient, on its definitive agreement to acquire Inozyme Pharma for $4 per share in an all-cash transaction valued at approximately $270 million.

Cooley advised Chimerix (Nasdaq: CMRX), a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, on its definitive agreement to be acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $8.55 per share in cash – totaling approximately $935 million.